Abstracts

WHO SHOULD SUBMIT

Abstract and Informative Case Report submission is open to physician-scientists, research scientists, clinicians and medical education professionals. This is a multi-disciplinary meeting; abstract submission is highly recommended for young investigators, fellows, junior scientists and trainees, who will benefit from close interaction with senior colleagues regarding his/her work.

ONLINE SUBMISSION

Abstracts and Informative Case Reports must be submitted online via the CSCTR / MWAFMR abstract submission site. To ensure your data is entered correctly, follow all instructions carefully.  Complete instructions for submission available online. When you completed the abstract submission process, print a copy of your submitted abstract for your files.

Abstract Example      Case Report Example

IMPORTANT DATES TO REMEMBER

Submissions Open October 2024

Submission Deadline

January 22, 2025
11:59 pm Central Time
Author Result Notifications
(all submitters will receive notification
regardless of the result)
February 12-19, 2025
Author Accept / Decline Deadline by February 27, 2025

NOTE: If your abstract is accepted and you are unable to attend the meeting, please decline the invitation to present. You must attend and present your abstract(s) as assigned to be published in the Journal of Investigative Medicine.

REVIEW

All abstracts submitted will be graded by CSCTR / MWAFMR Midwest Clinical & Translational Research Meeting program committee members. The review process typically takes 2-3 weeks.

RESEARCH CATEGORIES

For each research abstract and informative case report, you will be asked to select one of the following research categories of clinical and translational research.  Identifying a research category will help us to select the most appropriate reviewers and develop sessions.

  • Case Report: An article that describes and interprets an individual case, often written in the form of a detailed story. This may include unique cases that cannot be explained by known diseases or syndromes; cases that show an important variation of a disease or condition; cases that show unexpected events that may yield new or useful information; cases in which one patient has two or more unexpected diseases or disorders.
  • T0 Research: basic biomedical research, including preclinical and animal studies, not including interventions with human subjects.
  • T1 Research: translation to humans, including proof of concept studies, Phase 1 clinical trials, and focus on new methods of diagnosis, treatment, and prevention in highly controlled settings.
  • T2 Research: translation to patients, including Phase 2 and 3 clinical trials, and controlled studies leading to clinical application and evidence-based guidelines.
  • T3 Research: translation to practice, including comparative effectiveness research, post-marketing studies, clinical outcomes research, as well as health services, and dissemination & implementation research.
  • T4 Research: translation to communities, including population level outcomes research, health informatics.

AGE STRATUM

For each research abstract and informative case report, you will be asked to select one of the following age strata.  Your answer will help us to select appropriate reviewers and develop sessions.

  • Adult
  • Pediatric / adolescent
  • Both

RESEARCH TOPICS

For each research abstract and informative case report, you will be asked to select a primary and secondary research topic.

Cardiology / Cardiovascular Disease
Calcium and Bone Disorders
Dermatology
Diagnosis or Treatment of a Disease Process or Clinical Syndromes
Endocrinology / Metabolism
Environmental Factors Affecting Health
Epidemiology
Gastroenterology / Clinical Nutrition
Genetic and Molecular Medicine
Geriatrics and Aging
General Medicine
Health Disparities / Diversity / Equity / Inclusion / Social Determinants / Ethics
Hematology and Oncology / Bone Marrow Transplant
Infectious Disease / Immunization
Nephrology
Neurology
Psychiatry
Pathophysiology / Pathology
Pulmonary / Critical Care
Rheumatology
Immunology / Allergy
Transplant Medicine
Surgery

REPORT LENGTH

There is a limit of 3,800 characters (including spaces) for the text of your abstract or informative case report submission. The character limit does not count authors, institutions, title or table(s).

NO SUBMISSION FEES

There is no longer any fees associated with abstract submissions for the upcoming meeting. This change reflects the Societies' commitment to making the event more accessible to a broader audience and encouraging greater participation from researchers, students, and professionals in the community.

Whether you are a seasoned expert or new to the field, you can now submit your research, ideas, and findings without any financial barriers. We look forward to receiving your submissions and showcasing a wide range of innovative work at the Midwest Clinical & Translational Research Meeting.

AWARDS

Are you eligible for one or more awards? Visit the awards page for additional information and qualifications. During the abstract submission process you will be asked for which awards you are eligible. You may select all awards for which you are eligible. However, of the awards you are eligible for and you selected in the abstract submission form, only one award will be offered. You are unable to apply for an award after the abstract submission closes.

AUTHOR ATTENDANCE REQUIREMENT

By submitting an abstract or informative case report to the Midwest Clinical & Translational Research Meeting, you agree that at least one author will attend the meeting if the abstract or informative case report is accepted. An author must be available to present on the date and time assigned by the Meeting program committee. Authors will be notified of presentation times at the time of, or shortly after, notification of acceptance and are expected to make appropriate travel arrangements to ensure that at least one author is present.

Only the abstract(s) of presenting authors who attended the meeting will be published in the Journal of Investigative Medicine. Abstract(s) of no show authors will not be published.